Ramacciotti, Eduardo 
; Agati, Leandro Barile; Calderaro, Daniela ; Volpiani, Giuliano Giova; Oliveira, Caroline Candida Carvalho de; Aguiar, Valéria Cristina Resende; Rodrigues, Elizabeth; Sobreira, Marcone Lima ; Joviliano, Edwaldo Edner ; Dusilek, Cesar ; Itinose, Kenji ; Dedivitis, Rogério Aparecido ; Cortina, André Sementilli ; Sanches, Suzanna Maria Viana ; Moraes, Nara Franzin de; Tierno, Paulo Fernando Guimarães Morando Marzocchi ; Oliveira, André Luiz Malavasi Longo de; Tachibana, Adriano ; Chate, Rodrigo Caruso; Santos, Marcus Vinícius Barbosa; Cavalcante, Bruno Bezerra de Menezes ; Moreira, Ricardo Cesar Rocha; Chiann, Chang ; Tafur, Alfonso ; Spyropoulos, Alex C.; Lopes, Renato D
Fonte: American Heart Journal. Unidades: FM, FMRP, IME
Assuntos: COVID-19, TROMBOSE, BIOESTATÍSTICA
ABNT
RAMACCIOTTI, Eduardo et al. Medically ill hospitalized patients for COVID-19 thrombosis extended prophylaxis with rivaroxaban therapy: rationale and design of the MICHELLE trial. American Heart Journal, v. 242, p. 115-122, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2021.08.016. Acesso em: 02 nov. 2025.APA
Ramacciotti, E., Agati, L. B., Calderaro, D., Volpiani, G. G., Oliveira, C. C. C. de, Aguiar, V. C. R., et al. (2021). Medically ill hospitalized patients for COVID-19 thrombosis extended prophylaxis with rivaroxaban therapy: rationale and design of the MICHELLE trial. American Heart Journal, 242, 115-122. doi:10.1016/j.ahj.2021.08.016NLM
Ramacciotti E, Agati LB, Calderaro D, Volpiani GG, Oliveira CCC de, Aguiar VCR, Rodrigues E, Sobreira ML, Joviliano EE, Dusilek C, Itinose K, Dedivitis RA, Cortina AS, Sanches SMV, Moraes NF de, Tierno PFGMM, Oliveira ALML de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Spyropoulos AC, Lopes RD. Medically ill hospitalized patients for COVID-19 thrombosis extended prophylaxis with rivaroxaban therapy: rationale and design of the MICHELLE trial [Internet]. American Heart Journal. 2021 ; 242 115-122.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.ahj.2021.08.016Vancouver
Ramacciotti E, Agati LB, Calderaro D, Volpiani GG, Oliveira CCC de, Aguiar VCR, Rodrigues E, Sobreira ML, Joviliano EE, Dusilek C, Itinose K, Dedivitis RA, Cortina AS, Sanches SMV, Moraes NF de, Tierno PFGMM, Oliveira ALML de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Spyropoulos AC, Lopes RD. Medically ill hospitalized patients for COVID-19 thrombosis extended prophylaxis with rivaroxaban therapy: rationale and design of the MICHELLE trial [Internet]. American Heart Journal. 2021 ; 242 115-122.[citado 2025 nov. 02 ] Available from: https://doi.org/10.1016/j.ahj.2021.08.016
